MORRISVILLE, N.C., Jan. 14, 2025 /PRNewswire/ — Mercalis Inc., an integrated life sciences commercialization company that provides comprehensive solutions that span the biopharmaceutical value chain, today announced a successful 2024 fiscal year with notable achievements in key strategic areas.
“2024 was a tremendous year for Mercalis as we continued to crystallize our capabilities as a full-service life sciences commercialization platform,” said Scott Dulitz, Mercalis’s Chief Executive Officer. “As we began the year, we launched innovative Patient Services programs targeting complex disease areas, including oncology, rare conditions, and CNS. These achievements were driven by our team’s dedication, adaptability, and cutting-edge technology platforms. The synergy between our Patient Support Services, Data & Insights, and Healthcare Provider segments continues to grow, creating greater value for our clients throughout the patient, prescription, and product journeys. With a strong foundation in place, we’re excited to build on this momentum in 2025, maintaining our unwavering focus on enhancing the patient …